May 7, 2020 / 12:58 PM / 22 days ago

BRIEF-Rubius Therapeutics Announces Dosing Of First Patient In Cellular Therapy Trial For Treatment Of Solid Tumors

May 7 (Reuters) - Rubius Therapeutics Inc:

* RUBIUS THERAPEUTICS ANNOUNCES DOSING OF FIRST PATIENT IN PHASE 1/2 TRIAL OF RTX-240, AN ALLOGENEIC CELLULAR THERAPY, FOR THE TREATMENT OF SOLID TUMORS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below